ADORA2A and Parkinson disease: Thus, A2AR antagonists seem to have a dual impact on the evolving PD neuropathology and motor deficits, with a greater impact when applied earlier and attenuating synaptotoxicity, but also able to reduce the overt neurodegeneration of DA neurons when applied later.